Amundi’s Emergent Biosolutions EBS Stock Holding History

Amundi’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,210	Closed	-$47K	–	2021
2023 Q2	$47K	Buy	6,210 +168	+3%	+$1.56K	﹤0.01%	1904
2023 Q1	$62.1K	Buy	+6,042	New	+$73K	﹤0.01%	1846

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Amundi's EBS Position: Q3 2023 in Review

Amundi sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 6,210 shares — an estimated $47K sold.

Amundi first reported a position in EBS in Q1 2023 and held it in 2 quarters. The position peaked at $62.1K in Q1 2023. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

Amundi reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
Amundi sold 6,210 Emergent Biosolutions shares in Q3 2023, an estimated $47K.
Amundi first reported a position in Emergent Biosolutions in Q1 2023 and held it in 2 quarters.
Amundi's Emergent Biosolutions position peaked at $62.1K in Q1 2023.
162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Amundi's 13F filing for Q3 2023, filed 14 Nov 2023.